Credit Suisse Keeps Their Hold Rating on Edwards Lifesciences (EW)

Credit Suisse analyst Lorenzo Biasio maintained a Hold rating on Edwards Lifesciences (EWResearch Report) yesterday and set a price target of $78.00. The company’s shares closed yesterday at $79.09.

According to TipRanks, Biasio is a 4-star analyst with an average return of 5.5% and a 59.07% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Boston Scientific, Coherus Biosciences, and Edwards Lifesciences.

In addition to Credit Suisse, Edwards Lifesciences also received a Hold from Raymond James’s Jayson Bedford in a report issued yesterday. However, on February 1, Evercore ISI maintained a Buy rating on Edwards Lifesciences (NYSE: EW).

See Insiders’ Hot Stocks on TipRanks >>

Based on Edwards Lifesciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.35 billion and a net profit of $398.4 million. In comparison, last year the company earned a revenue of $1.33 billion and had a net profit of $335.3 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.

Read More on EW:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More